Physician
Infectious Disease
Dr. Peter J. Piliero, MD
|
|
Give Review
Peter J. Piliero, MD practices Infectious Disease. He graduated from Stony Brook University School of Medicine. Doctor Peter J. Piliero, MD is a published doctor as well. He has 40 publications published. The latest was: Eastern equine encephalitis presenting as focal neuroradiographic abnormalities: case report and review.
Publications
- Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients: Observational Data from the Randomized POTENT Trial.
- Susceptibility of HIV-1 to tipranavir and other antiretroviral agents in treatment-experienced patients: The UTILIZE Study.
- Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.
- Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis.
- Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
- Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
- Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients.
- Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
- Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
- Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 cli...
- Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.
- Strategies for initiating combination antiretroviral therapy.
- Developments in HIV treatments: strategies for success.
- Atazanavir: A novel once-daily protease inhibitor.
- Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
- An assessment of herbal therapy use, adherence and utilization of pharmacy services in HIV clinics.
- Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.
- Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.
- Buffalo hump: what the experts suggest.
- Diaphragmatic paralysis due to isolated phrenic neuropathy in an HIV-infected man.
- Use of ultrasonography-assisted liposuction for the treatment of human immunodeficiency virus-associated enlargement of the dorsocervical fat pad.
- In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12...
- Pharmacodynamics and clinical use of anti-HIV drugs.
- Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs.
- Early factors in successful anti-HIV treatment.
- Simplified regimens for treating HIV infection and AIDS.
- Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.
- Mechanisms of lipid elevations associated with the treatment of patients with HIV infection.
- Editorial comment: fewer prescribing errors in the 21st Century?
- Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
- T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretrovi...
- Guillain-Barré syndrome associated with immune reconstitution.
- Antiretroviral rounds. Failure to achieve full virologic suppression.
- Case report. Hepatitis B virus and HIV coinfection.
- Atazanavir: a novel HIV-1 protease inhibitor.
- Interaction between ritonavir and statins.
- Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
- HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy.
- Eastern equine encephalitis presenting as focal neuroradiographic abnormalities: case report and review.
Schools
State University of New York Health Science Center At Stony Brook
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Education
-
New York Presbyterian Hospital - Columbia Campus -
Stony Brook University School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Douglas A. Finch, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Geoffrey M. Mukwaya, MB CHB
This Doctor is OpenDoctor Recommended.
|